[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Gupta K, Mathur VS: Diagnosis of pericardial disease using percutaneous biopsy: case report and literature review. Tex Heart Inst J; 2003;30(2):130-3
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of pericardial disease using percutaneous biopsy: case report and literature review.
  • We describe the case of a 75-year-old man who presented with a large pericardial effusion and an intrapericardial mass.
  • Malignant thymoma with pericardial involvement was diagnosed by percutaneous pericardial tumor biopsy.
  • The pleural effusion was not malignant.
  • The patient underwent further oncologic evaluation followed by adjunctive chemotherapy and radical extirpation of the tumor.
  • He remains asymptomatic and free of disease 24 months after the procedure.
  • We also discuss the role of percutaneous biopsy in the diagnosis of pericardial diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1980 Sep-Oct;24(5):401-12 [6933801.001]
  • [Cites] Am Heart J. 1987 Mar;113(3):785-90 [3548297.001]
  • [Cites] Cathet Cardiovasc Diagn. 1988;15(2):92-4 [3180214.001]
  • [Cites] Am Heart J. 1991 Sep;122(3 Pt 1):879-82 [1877471.001]
  • [Cites] Am J Cardiol. 1979 Nov;44(6):1110-4 [495505.001]
  • [Cites] Int J Cardiol. 1992 Nov;37(2):258-60 [1452386.001]
  • [Cites] Am J Cardiol. 1994 Aug 1;74(3):288-91 [8037141.001]
  • [Cites] Arch Intern Med. 1979 Feb;139(2):231-4 [434978.001]
  • [Cites] Arch Intern Med. 1979 Apr;139(4):407-12 [434993.001]
  • [Cites] Am Heart J. 1991 Sep;122(3 Pt 1):882-3 [1877472.001]
  • (PMID = 12809255.001).
  • [ISSN] 0730-2347
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC161899
  •  go-up   go-down


2. Zhang PJ, Brooks JS, Goldblum JR, Yoder B, Seethala R, Pawel B, Gorman JH, Gorman RC, Huang JH, Acker M, Narula N: Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival. Hum Pathol; 2008 Sep;39(9):1385-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival.
  • Although cardiac sarcomas are rare in comparison to their soft tissue counterparts, they are the second most common type of primary cardiac neoplasm.
  • A series of 27 cardiac sarcomas removed at surgery for curative and diagnostic intent were reviewed for clinicopathologic features with correlation to available postoperative follow-up data in 17 patients.
  • There were 6 angiosarcomas, 6 myxofibrosarcomas, 3 malignant peripheral nerve sheath tumors, 3 leiomyosarcomas, 2 synovial sarcomas, 1 epithelioid hemangioendothelioma, 1 chondrosarcoma, 1 osteosarcoma, and 4 poorly differentiated sarcomas.
  • There were 20 cases that arose in the atria/pulmonary vessels, 4 in the ventricles, 1 in mitral valve, and 2 in epi/pericardium.
  • Six high-grade and 1 low-grade tumors were also treated with adjuvant chemotherapy and/or radiation.
  • In 17 patients with follow-up data, 6 of 12 patients with high-grade tumor died (4 within 5 days of the initial surgery, 1 in 21 months, and 1 in 131 months), and 1 patient with moderate-grade tumor and all 4 patients with low-grade tumor were alive without evidence of disease at the end of follow-up.
  • Tumor grade appeared to be prognostically important in cardiac sarcoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 Jun;69(6):1949-51 [10892961.001]
  • [Cites] Z Kardiol. 2002 Apr;91(4):352-6 [12063709.001]
  • [Cites] J Heart Lung Transplant. 2002 Oct;21(10):1135-9 [12398881.001]
  • [Cites] Rev Esp Cardiol. 2003 Apr;56(4):408-11 [12689577.001]
  • [Cites] Chest. 2003 May;123(5):1766-8 [12740300.001]
  • [Cites] Thorac Cardiovasc Surg. 2004 Apr;52(2):77-81 [15103579.001]
  • [Cites] Ann Surg. 1980 Feb;191(2):127-38 [7362282.001]
  • [Cites] Hum Pathol. 1982 Jul;13(7):640-5 [7084941.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Arch Pathol Lab Med. 1985 Oct;109(10):943-5 [3840005.001]
  • [Cites] Chest. 1987 Jul;92(1):177-9 [3595230.001]
  • [Cites] Chest. 1987 Nov;92(5):860-2 [3665601.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:183-91 [2237900.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:192-5 [2237901.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):906-10 [2039319.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):999-1001 [2039335.001]
  • [Cites] Ann Thorac Surg. 1991 Oct;52(4):886-95 [1929651.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):387-95 [1728367.001]
  • [Cites] Am Heart J. 1992 Jan;123(1):232-4 [1729836.001]
  • [Cites] Aust N Z J Med. 1991 Dec;21(6):881-3 [1818549.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1992;26(3):233-6 [1287840.001]
  • [Cites] J Cardiovasc Surg (Torino). 1993 Dec;34(6):529-33 [8300722.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):374-82 [7997732.001]
  • [Cites] J Heart Lung Transplant. 1995 Mar-Apr;14(2):382-6 [7779860.001]
  • [Cites] Hum Mol Genet. 1995 Jun;4(6):1097-9 [7655467.001]
  • [Cites] Histopathology. 1997 Apr;30(4):349-52 [9147083.001]
  • [Cites] Jpn Circ J. 1997 Sep;61(9):795-7 [9293411.001]
  • [Cites] Ann Diagn Pathol. 1998 Jun;2(3):167-72 [9845736.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1624-8 [9862574.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):194-8 [10102352.001]
  • [Cites] Histopathology. 1999 Apr;34(4):295-304 [10231396.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jun;29(6):925-32 [16675225.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):188-9 [17409853.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2007 Jan;55(1):19-22 [17444167.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1134-42 [17914083.001]
  • (PMID = 18602663.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL063954
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS522251; NLM/ PMC4081532
  •  go-up   go-down


3. Karpuz V, Ikitimur B, Karpuz H: [A survey of heart tumors: clinical and echocardiographic approach]. Anadolu Kardiyol Derg; 2007 Dec;7(4):427-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heart tumors can be primary in origin, can develop from direct extension of a neighboring tumor or they can be the manifestation of metastasis of a distant tumor.
  • Myxomas are the most frequently encountered primary benign cardiac tumors.
  • Primary malignant tumors of the heart are rare, and they are mostly sarcomatous in structure.
  • Secondary heart tumors constitute a wide spectrum, nevertheless they most frequently originate from lung cancer, breast cancer and hematological malignancies.
  • Heart tumors may involve myocardium, endocardium, epicardium, pericardium, or any combination of the aforementioned layers.
  • On the other hand, the usual site for metastasis to the heart is the pericardium.
  • Magnetic resonance imaging and computerized tomography may be helpful for selected cases.
  • Surgery is the principal therapeutic option in benign tumors and when recurrences are not taken into account, they have favorable prognoses.
  • Since surgical resection is usually incomplete in malignant tumors, therapy must be individualized for each patient; even with adjuvant chemotherapy, postoperative survival is usually short.
  • [MeSH-major] Heart Neoplasms / diagnosis
  • [MeSH-minor] Echocardiography, Transesophageal. Fibroma / diagnosis. Fibroma / pathology. Fibroma / radiography. Fibroma / ultrasonography. Hemangioma / diagnosis. Hemangioma / pathology. Hemangioma / radiography. Hemangioma / ultrasonography. Humans. Magnetic Resonance Imaging. Myoma / diagnosis. Myoma / pathology. Myoma / radiography. Myoma / ultrasonography. Myxoma / diagnosis. Myxoma / pathology. Myxoma / radiography. Myxoma / ultrasonography. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065342.001).
  • [ISSN] 1308-0032
  • [Journal-full-title] Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
  • [ISO-abbreviation] Anadolu Kardiyol Derg
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 49
  •  go-up   go-down


Advertisement
4. Shintani Y, Ohta M, Hazama K, Miyoshi S, Kagisaki K, Matsuda H: Thymic carcinoma successfully resected with superior vena cava after chemoradiotherapy. Jpn J Thorac Cardiovasc Surg; 2001 Dec;49(12):717-21
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 57-year-old woman hospitalized for thymic cancer invading the superior vena cava and left brachiocephalic vein evidenced both pleural and pericardial effusion.
  • After chemotherapy with cisplatin and docetaxel and concurrent radiotherapy, the entire tumor was successfully resected along with the pericardium, superior vena cava, and left brachiocephalic vein, followed by vascular reconstruction.
  • Pathologically, viable tumor cells were identified only in the center of the tumor as anaplastic cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / surgery. Paclitaxel / analogs & derivatives. Taxoids. Thymus Neoplasms / surgery. Vena Cava, Superior / surgery
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Middle Aged. Pericardial Effusion / etiology. Pleural Effusion, Malignant / etiology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11808095.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 10
  •  go-up   go-down


5. Yu L, Gu TX, Shi EY, Xiu ZY, Fang Q: [Diagnosis and therapy of primary malignant tumors of the heart and pericardium]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):230-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of primary malignant tumors of the heart and pericardium].
  • OBJECTIVE: To summarize and analyze the experience in diagnosis and treatment of primary malignant tumors of the heart and pericardium.
  • METHODS: The clinical data of 24 patients with malignant tumors of the heart and pericardium treated in our hospital between Jun.
  • RESULTS: All 24 patients received surgical treatment.
  • CONCLUSION: Echocardiography, CT, MRI, 3D-CT, CT of coronary artery and cardiac angiography are helpful for the diagnosis and selection of operation mode.
  • Histological examination is necessary for the final diagnosis.
  • Early diagnosis and surgical resection of the tumor as complete as possible, and combination with post-operative radiotherapy and/or chemotherapy may improve the survival of the patients.
  • [MeSH-major] Heart Neoplasms / diagnosis. Heart Neoplasms / surgery. Mesothelioma / diagnosis. Mesothelioma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Myxoma / diagnosis. Myxoma / surgery. Pericardium / surgery. Retrospective Studies. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615268.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Hasegawa S, Ito H, Kojima Y, Nakayama H, Wada N, Inui K, Imoto K, Rino Y, Takanashi Y: [A case of thymic cancer with pericardial tamponade as initial manifestation]. Gan To Kagaku Ryoho; 2006 Jan;33(1):79-82
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of thymic cancer with pericardial tamponade as initial manifestation].
  • We report a case of thymic cancer with pericardial tamponade in a 70-year-old woman.
  • CT scan showed a mediastinal mass and massive pericardial effusion.
  • The effusion was serous fluid, not bloody, and no malignant cells were found.
  • The patient underwent a tumor resection, and the final pathological diagnosis was squamous cell carcinoma of the thymus.
  • In a review of 14 cases of thymic tumor with pericardial tamponade as initial manifestations in the Japanese literature,there were only three cases of thymic cancer.
  • The prognosis was reported to be extremely poor.Some reports showed the effectiveness of chemotherapy and irradiation therapy.
  • We should keep looking for the best treatment for this disease.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Cardiac Tamponade / etiology. Thymus Neoplasms / complications
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Combined Modality Therapy. Female. Humans. Liver Neoplasms / secondary. Pericardial Effusion / etiology

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410702.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Debourdeau P, Gligorov J, Teixeira L, Aletti M, Zammit C: [Malignant cardiac tumors]. Bull Cancer; 2004 Nov;91 Suppl 3:136-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant cardiac tumors].
  • Cardiac neoplasms are a rare occurrence in clinical practice.
  • The various frequencies of primary and secondary malignant tumors vary from report to report, approximately 1% in most autopsy series and 4% in cancer patient's autopsies.
  • Cardiac malignancies account for less 1% of cardiac surgery and about for 0.1% of cardiac echographic studies.
  • The presence of metastatic tumor to the heart usually indicates widespread metastases.
  • Lung carcinomas are the most commonly encountered tumor followed by breast and pancreas cancer and melanoma.
  • Apart from primary pericardial mesothelioma, primary cardiac tumors are high-grade sarcomas with a high metastatic potency that often becomes evident early after surgery.
  • The signs of cardiac neoplasms are divided into systemic symptoms (fever, arthralgias and myalgias), cardiac symptoms (congestive heart failure, arrhythmia, chest pain) and uncommon embolisms.
  • Diagnosis is actually made easier with cardiac echography.
  • Cardiac RMI is helpful to estimate vessels and pericardium involvement.
  • Due to its poor prognosis, treatment of cardiac metastases is restricted to best supportive care.
  • For primary cardiac neoplasms, surgery must be carefully discussed because operative intervention is often followed by rapid widespread metastases that adjuvant chemotherapy cannot avoid in most cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899620.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 53
  •  go-up   go-down


8. Catalano A, Graciotti L, Rinaldi L, Raffaelli G, Rodilossi S, Betta P, Gianni W, Amoroso S, Procopio A: Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer; 2004 Apr 10;109(3):322-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention.
  • Malignant mesothelioma (MM) remains the most lethal pleural, peritoneal and pericardial cancer.
  • Unlike primary normal mesothelial cells, the selective cyclooxygenase (COX)-2 inhibitor celecoxib reduced the in vitro proliferation of several MM cells derived from previously untreated MM patients.
  • Celecoxib, in a dose- and time-dependent manner, induced MM cell apoptosis, which involved decreased Akt phosphorylation, loss of Bcl-2 and Survivin protein expression and caspase-3 activation.
  • These data demonstrate that celecoxib may have antitumor properties in MM and provide a rationale for the therapeutic use of celecoxib in combination with a selective VEGF inhibitor.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Mesothelioma / drug therapy. Protein-Serine-Threonine Kinases. Proto-Oncogene Proteins / antagonists & inhibitors. Sulfonamides / therapeutic use
  • [MeSH-minor] Animals. Apoptosis. Caspase 3. Caspases / metabolism. Celecoxib. Chemoprevention. Cyclooxygenase Inhibitors / pharmacology. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt. Proto-Oncogene Proteins c-bcl-2 / metabolism. Pyrazoles. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 14961568.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazoles; 0 / Sulfonamides; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


9. Sakai T, Kimura D, Tsushima T, Hatanaka R, Yamada Y, Fukuda I: [Assessment of surgical treatment for lung cancer with pericardial or left atrial invasion]. Kyobu Geka; 2010 May;63(5):360-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of surgical treatment for lung cancer with pericardial or left atrial invasion].
  • We evaluated surgical results for the patients who underwent pulmonary resection combined with pericardial or left atrial resection due to locally advanced non-small cell lung cancer (NSCLC).
  • Seven patients who underwent pericardial resection (T3 group) and 4 patients who underwent resection of the left atrium (T4 group) were included in this study, and clinical findings and prognosis were evaluated.
  • Histology of the cancer was squamous cell carcinoma in all patinets.
  • Induction chemotherapy was performed in 75.0% of T4 group.
  • Extended resection of pericardium or left atrium for patients with N2 disease of NSCLC is not recommended.
  • When invasion to pericardium or left atrium is diagnosed during surgery, extended resection should be indicated in patient without N2 metastasis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Heart Atria / surgery. Lung Neoplasms / surgery. Pericardium / surgery
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Invasiveness. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446602.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Loggie BW: Malignant peritoneal mesothelioma. Curr Treat Options Oncol; 2001 Oct;2(5):395-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peritoneal mesothelioma.
  • This paper summarizes the author's thoughts about the use of cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy (CS-IPHC) for treatment of peritoneal malignant mesothelioma.
  • Pleural malignant mesotheliomas are by far more common (about ten- to thirty-fold) than the peritoneal variants (2.2 cases per 1 million in the US).
  • Other locations (pericardium, tunica vaginalis) are very rare.
  • It is well known that chemotherapy for mesothelioma is largely unsatisfactory, and measurement of treatment responses can be difficult.
  • Single agent responses are all less than 20% with currently available agents for systemically administered drugs.
  • Multiple drug combinations are typically more toxic, and have yielded little consistent demonstrable benefit with major studies reporting median survivals consistently under a year.
  • With peritoneal malignant mesothelioma, malignant ascites is a common presentation and a major factor in disease-related morbidity and mortality.
  • Interperitoneal administration of agents is attractive, but drug distribution is an issue, as are response rates and durability.
  • Multiple treatments are required; further, all neoplasms with peritoneal dissemination are typically understaged by current radiologic tests (CT, MRI), and the variable uptake of sugar by the small bowel limits the use of positron-emission tomography (PET) imaging for peritoneal malignant mesothelioma.
  • Also, symptoms of bowel obstruction are not uncommon, and any mechanical component of obstruction will not improve with any form of chemotherapy.
  • 2) tumor debulking, as possible, and treatment of mechanical obstruction as well as prevention of impending obstruction by resection or bypass; and 3) preparation for the use of intra-operative hyperthermic chemotherapy perfusion.
  • This approach has been associated with rapid clinical symptom improvement, as well as a reliable and durable resolution of ascites with a single therapy.
  • The inability to provide effective systemic therapy to maintain or consolidate these gains is problematic.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced. Mesothelioma / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Ascites / etiology. Combined Modality Therapy. Diagnostic Imaging. Digestive System Surgical Procedures. Epidemiologic Methods. Humans. Infusions, Parenteral. Intestinal Obstruction / etiology. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3696-700 [10919635.001]
  • [Cites] Lancet. 2001 Feb 10;357(9254):444-5 [11273069.001]
  • [Cites] Perfusion. 1999 Mar;14(2):141-5 [10338326.001]
  • [Cites] Am Surg. 2000 Jun;66(6):561-8 [10888132.001]
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):65-73 [11237495.001]
  • [Cites] Am Surg. 1997 Feb;63(2):137-43 [9012427.001]
  • [Cites] Cancer Treat Res. 1996;81:193-211 [8834586.001]
  • [Cites] Ann Surg Oncol. 1999 Sep;6(6):582-90 [10493628.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2317-21 [10472351.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Cancer J Sci Am. 1997 May-Jun;3(3):174-9 [9161783.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] J Surg Oncol. 2000 Sep;75(1):55-8 [11025463.001]
  • [Cites] JAMA. 1998 Jan 28;279(4):292-5 [9450713.001]
  • (PMID = 12057102.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


11. Papi M, Genestreti G, Tassinari D, Lorenzini P, Serra S, Ricci M, Pasquini E, Nicolini M, Pasini G, Tamburini E, Fattori PP, Ravaioli A: Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori; 2005 May-Jun;91(3):276-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pericardial mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis.
  • Malignant pericardial mesothelioma is an uncommon variety of a primary malignant cardio-pericardial tumor and it is a highly lethal and fortunately rare cardiac neoplasm.
  • The presentation of pericardial mesothelioma is aspecific and pathologically mesothelioma is not the most common among primary tumors of the pericardium.
  • Antemortem diagnosis is difficult and distant metastases are extremely rare.
  • The treatment for advanced primary pericardial mesothelioma is usually palliative because the tumor is resistant to radiotherapy and chemotherapy.
  • In this paper we report two cases of patients with primary mesothelioma of the pericardium without a definite history of asbestos exposure.
  • [MeSH-major] Heart Neoplasms / pathology. Mesothelioma / pathology. Pericardium / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Humans. Male. Prognosis. Survival

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206657.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


12. Palumbo C, Bei R, Procopio A, Modesti A: Molecular targets and targeted therapies for malignant mesothelioma. Curr Med Chem; 2008;15(9):855-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targets and targeted therapies for malignant mesothelioma.
  • Malignant mesothelioma is a highly invasive tumor originating from the mesothelial linings of the pleura, peritoneum and pericardium.
  • It is seldom amenable to surgical intervention and poorly responsive to radiotherapy, leaving chemotherapy as the main therapeutic option for most patients.
  • The development of effective drug regimens against mesothelioma has proven extremely difficult and a standard first-line treatment for patients with unresectable tumors has not been established until recently.
  • Despite the benefits obtained with this newly validated standard of care, which is based on the combination of pemetrexed and cisplatin, the prognosis for mesothelioma patients remains poor, median survival is still less than two years and more active treatments are urgently needed.
  • This article will focus on the molecular basis providing the rationale for targeted interventions against mesothelioma and will review targeted agents under evaluation as new potential therapeutic options for mesothelioma patients.
  • The agents targeting vascular endothelial growth factor signaling are of particular interest, due to the involvement of this pathway both in tumor angiogenesis and autocrine stimulation of mesothelioma cell growth.
  • Alternative approaches are based on inhibitors of the ubiquitin-proteasome pathway and of histone deacetylases which, notwithstanding the functional divergence of the corresponding targets, share the ability to determine a wide modulation of the cancer cell phenotype that can lead to cell cycle arrest, apoptosis and sensitization to different antineoplastic treatments.
  • [MeSH-major] Antineoplastic Agents / metabolism. Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Mesothelioma / drug therapy. Mesothelioma / metabolism. Receptors, Growth Factor / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. GPI-Linked Proteins. Histone Deacetylase Inhibitors. Histone Deacetylases / metabolism. Humans. Immunotoxins / therapeutic use. Membrane Glycoproteins / metabolism. Proteasome Endopeptidase Complex / metabolism. Proteasome Inhibitors. Ubiquitin / antagonists & inhibitors. Ubiquitin / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18473795.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / GPI-Linked Proteins; 0 / Histone Deacetylase Inhibitors; 0 / Immunotoxins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Proteasome Inhibitors; 0 / Receptors, Growth Factor; 0 / SS1(dsFv)PE38; 0 / Ubiquitin; 0 / Vascular Endothelial Growth Factor A; 0 / mesothelin; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 3.5.1.98 / Histone Deacetylases
  • [Number-of-references] 216
  •  go-up   go-down


13. Saito T, Tamaru J, Kayao J, Kuzuu Y, Wakita H, Mikata A: Cytomorphologic diagnosis of malignant lymphoma arising in the heart: a case report. Acta Cytol; 2001 Nov-Dec;45(6):1043-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic diagnosis of malignant lymphoma arising in the heart: a case report.
  • BACKGROUND: Primary malignant lymphoma of the heart is extremely rare.
  • Because its clinical signs and symptoms are typically nonspecific, it is often very difficult to detect cardiac involvement while the patient is alive.
  • We describe a case of malignant lymphoma involving predominantly the heart and pericardium and diagnosed by pericardiac effusion cytology antemortem.
  • Echocardiography revealed a low-echoic tumor mass close to the right ventricular wall and massive pericardiac effusion.
  • Diagnosis of diffuse large B-cell lymphoma was made by cytomorphologic examination and flow cytometry of the tumor cells obtained from the effusion.
  • Although chemotherapy was instituted immediately, the patient died of progressive heart failure.
  • CONCLUSION: From the experience in this case, we conclude that cytopathologic examination of sonographically guided aspiration of the cardiovascular region is very useful for antemortem diagnosis of primary malignant lymphoma of the heart.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Therapy, Combination. Echocardiography. Fatal Outcome. Female. Flow Cytometry. Heart Failure / etiology. Heart Failure / pathology. Humans. Immunophenotyping. Pericardial Effusion / diagnosis. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11726101.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


14. Watanabe S, Shimokawa S, Sakasegawa K, Nakamura Y, Sakata R: [Surgical treatment for malignant pleural mesothelioma in eight cases]. Kyobu Geka; 2000 Dec;53(13):1101-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for malignant pleural mesothelioma in eight cases].
  • Between 1987 and March 2000, we have operated on eight patients for malignant mesothelioma which consisted of four of localized type and four of diffuse type.
  • We have aggressively resected mesothelioma combined with chemotherapy whether the tumor was primary or recurrent, and concluded the following.
  • 1) In localized malignant mesothelioma, en-bloc primary tumor resection was possible and additional resection for recurrence was effective and useful for long time survival.
  • 2) In diffuse malignant mesothelioma, complete tumor resection was impossible to even perform pleuropneumonectomy accompanied with partial resection of pericardium and diaphragm and, therefore, the prognosis was poor in four patients and all died around one year.
  • 3) Because recurrent pattern for localized type was diffuse type, diagnosis and surgical treatment in early stage was essential for long time survival.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Diaphragm / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Pericardium / surgery. Pleura / surgery. Pneumonectomy. Prognosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11127555.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Shimoyama T, Yoshiya K, Yamato Y, Koike T, Honma K: Long-term survival after removal of a malignant peripheral nerve sheath tumor originating in the anterior mediastinum. Gen Thorac Cardiovasc Surg; 2009 Jun;57(6):310-4
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after removal of a malignant peripheral nerve sheath tumor originating in the anterior mediastinum.
  • Malignant peripheral nerve sheath tumors (MPNSTs; malignant schwannomas) rarely occur in the anterior mediastinum, and their prognosis is poor.
  • A 75-year-old man was referred to our hospital for examination of an anterior mediastinal tumor.
  • A computed tomography-guided percutaneous needle biopsy revealed only fibrosis.
  • The tumor was completely excised via a median sternotomy with partial resection of the pericardium and right upper lobe of the lung.
  • Thereafter, the tumor was diagnosed as a storiform-pleomorphic type of malignant fibrous histiocytoma.
  • The tumor was completely excised via a right posterolateral thoracotomy.
  • Reexamination of the primary and secondary tumors revealed an MPNST.
  • No recurrence was found up to 5 years after the second surgery without adjuvant chemotherapy or radiation therapy.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Mediastinal Neoplasms / surgery. Nerve Sheath Neoplasms / surgery. Pericardiectomy. Pneumonectomy. Sternum / surgery
  • [MeSH-minor] Aged. Biopsy, Needle. Fatal Outcome. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Thoracotomy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Jun 1;82(11):2191-203 [9610699.001]
  • [Cites] Chest. 1995 Aug;108(2):574-5 [7634904.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Oct;128(4):615-7 [15457164.001]
  • [Cites] J Chin Med Assoc. 2006 Jan;69(1):37-41 [16447925.001]
  • [Cites] Ann Thorac Surg. 2003 May;75(5):1645-8 [12735601.001]
  • [Cites] World J Surg Oncol. 2005 Oct 06;3:65 [16207383.001]
  • [Cites] Monaldi Arch Chest Dis. 2006 Dec;65(4):222-4 [17393668.001]
  • [Cites] Cancer. 1971 May;27(5):1190-201 [5581511.001]
  • [Cites] Respiration. 2000;67(3):346-7 [10867610.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • (PMID = 19533278.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Oechsle K, Aebert H, Teichmann R, Budach W, Kanz L, Ziemer G, Hartmann JT: Primary malignant sarcomas of the heart and great vessels - a single center experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):9044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant sarcomas of the heart and great vessels - a single center experience.
  • Prognosis is very poor because of locally advanced or metastatic stage at diagnosis.
  • All pts were symptomatic with reduction of vitality, anorexia, dyspnoea, or neurological symptoms at the time of reception.
  • Tumors were located in atrium [(n=5), left (3)/right (2)], Art. pulmonalis (n=3), Aorta (n=2), pericardium or left chamber, (n=1 each).
  • Five of these 6 pts underwent palliative resection to relieve the physiologic effects of the tumor.
  • Three out of 5 pts with curative intended surgery have subsequently developed recurrence within 6, 8 and 25 mos despite adjuvant treatment.
  • Palliative chemotherapy including adriamycin and ifosfamide has been applied in 7 pts and 4 pts attained some response to treatment (n=1 PR, n=3 SD).
  • Palliative radiation included 3 pts with brain metastases and a single pt with progressive primary tumor.
  • After a median follow up 13 mos (2 -28) 2 pts had NED, 3 pts are alive with disease and 7 pts have died due to tumor progression.
  • CONCLUSIONS: Pts with primary sarcomas of the heart and the great vessels were often of young age, and half of them presented with locally or distant advanced disease.
  • These pts should preferentially be referred to a tertiary Cancer Center immediately after diagnosis without preceding treatment attempts.
  • Although the majority of pts cannot be treated curatively due to the delay in diagnosis, an optimized treatment approach including neoadjuvant chemo-/radiotherapy might enhanced the rate of complete resection depending on the histological subtype and responsiveness to treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013704.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Nakakuki T, Masuoka H, Ishikura K, Seko T, Koyabu S, Tamai T, Sugawa M, Ito M, Nakano T: A case of primary cardiac lymphoma located in the pericardial effusion. Heart Vessels; 2004 Jul;19(4):199-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary cardiac lymphoma located in the pericardial effusion.
  • Primary cardiac lymphoma is a rare disorder with a poor prognosis.
  • We present here a case of 77-year-old woman who was diagnosed as having cardiac lymphoma antemortem according to a cytologic examination of the pericardial effusion.
  • Determination of the levels of serum-soluble interleukin-2 receptor and serum deoxythymidine kinase was useful for the diagnosis.
  • Echocardiography, computed tomography, magnetic resonance imaging, and gallium scan revealed neither lymphadenopathy nor tumor in the heart, so she was diagnosed as having malignant lymphoma that probably originated from the pericardium.
  • Systemic chemotherapy with CHOP (cyclophosphamide, farmorubicin, oncovin, and prednisolone) resulted in a complete resolution of the pericardial effusion.
  • She has been in remission 48 months after discontinuation of the chemotherapy.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma / diagnosis. Pericardial Effusion / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Prednisolone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15278395.001).
  • [ISSN] 0910-8327
  • [Journal-full-title] Heart and vessels
  • [ISO-abbreviation] Heart Vessels
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


18. Einama T, Sato K, Tsuda H, Mochizuki H: Successful treatment of malignant pericardial effusion, using weekly paclitaxel, in a patient with breast cancer. Int J Clin Oncol; 2006 Oct;11(5):412-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of malignant pericardial effusion, using weekly paclitaxel, in a patient with breast cancer.
  • We report a case of metastatic breast cancer with pericardial effusion that was successfully treated with weekly paclitaxel.
  • A diagnosis of cardiac tamponade due to breast cancer relapse was made, and the patient was treated with weekly paclitaxel (80 mg/m2) and insertion of a drainage catheter.
  • This treatment was effective in preventing reaccumulation of the pericardial effusion until her death.
  • The concentration of paclitaxel in the cardiac effusion was 45 ng/ml at 3 h, 15 ng/ml at 12 h, and less than 10 ng/ml at 24 h after paclitaxel infusion, indicating good transportation of the drug from the blood to the pericardial effusion.
  • These findings suggest that weekly intravenous infusion of paclitaxel could be effective for the treatment of patients with malignant pericardial effusion.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Paclitaxel / therapeutic use. Pericardial Effusion / therapy
  • [MeSH-minor] Cardiac Tamponade / etiology. Cardiac Tamponade / therapy. Drainage. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Staging. Pericardiocentesis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 2003 Aug;33(8):371-6 [14523055.001]
  • [Cites] JAMA. 1994 Jul 6;272(1):59-64 [8007081.001]
  • [Cites] JAMA. 1982 Feb 26;247(8):1143-8 [7057604.001]
  • [Cites] Semin Oncol. 1978 Jun;5(2):181-92 [353988.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Mar;31(3):449-51 [15045960.001]
  • [Cites] Clin Cancer Res. 1995 Jun;1(6):599-606 [9816021.001]
  • [Cites] J Surg Oncol. 1984 Sep;27(1):42-4 [6482451.001]
  • [Cites] Am J Med. 1978 Nov;65(5):808-14 [707539.001]
  • [Cites] Arch Intern Med. 1975 Jul;135(7):976-7 [1156057.001]
  • [Cites] Heart. 1996 Jan;75(1):67-71 [8624876.001]
  • [Cites] Am J Med. 1993 Aug;95(2):209-13 [8356985.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1697-1704 [7370925.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2061-8 [15169793.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Dec 27;44 Suppl:S15-30 [12505596.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):76-80 [1702345.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):14-8 [8630921.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1377-87 [8620412.001]
  • [Cites] Am Heart J. 1986 Jun;111(6):1138-42 [3716989.001]
  • [Cites] Cancer Treat Rep. 1987 Dec;71(12):1179-84 [2891442.001]
  • [Cites] Oncologist. 1998;3(6):373-389 [10388129.001]
  • (PMID = 17058141.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


19. Dorobantu M, Fruntelata A, Constantinescu D, Racoveanu I, Ardeleanu C, Tatu-Chitoiu G, Lazar IC: Primary left heart malignant fibrous histiocytoma. Eur J Echocardiogr; 2005 Jun;6(3):225-7
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary left heart malignant fibrous histiocytoma.
  • We present the case of a 53 years-old woman presenting with congestive heart failure and pleural and pericardial effusions, in whom transthoracic and transesophageal echocardiography revealed multilocular cardiac tumor involving the left atrium wall, extending into the pericardium.
  • Tumor was excised surgically and proved to be a malignant fibrous histiocytoma, primarily confined to the heart.
  • Despite surgery followed by chemotherapy, the patient died a few months later.
  • This is the 47th case of primary cardiac fibrous malignant histiocytoma reported in the literature.
  • The pericardial involvement has been only rarely reported.
  • Echocardiography was the method of diagnosis before rapid referral to surgery.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894243.001).
  • [ISSN] 1525-2167
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Sarjeant JM, Butany J, Cusimano RJ: Cancer of the heart: epidemiology and management of primary tumors and metastases. Am J Cardiovasc Drugs; 2003;3(6):407-21
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the heart: epidemiology and management of primary tumors and metastases.
  • Cardiac tumors, benign or malignant, are rare and most are benign.
  • The most common benign tumor is the cardiac myxoma.
  • Malignant cardiac tumors are usually sarcomas.
  • The pericardium can be the site of benign and malignant cardiac tumors, though metastatic tumors occur here far more commonly than do primary tumors.
  • Successful treatment for benign cardiac tumors is usually achieved by surgical resection.
  • Surgery for primary malignant tumors is, however, much less successful as complete resection is usually not possible.
  • Primary cardiac lymphoma may be successfully treated by chemotherapy.
  • Tumors that metastasize to the heart from other organs occur 100- to 1000-fold more commonly than primary cardiac tumors.
  • Metastatic spread to the heart has been identified in approximately one-fifth of all patients who have metastatic cancer with lung carcinoma being the most common primary tumor.
  • Symptoms of cardiac metastases vary, and they depend on the site and extent of the lesions.
  • Treatment varies depending on the pathology of the primary tumor.
  • However, the aim of treatment is usually symptomatic relief.
  • With the advent of AIDS, Kaposi's sarcoma and high grade B cell lymphomas have also been identified in cardiac tissue.
  • The aim of this article is to review the epidemiology, clinical presentation, pathology and treatment of cardiac tumors.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Carcinoid Heart Disease / diagnosis. Carcinoid Heart Disease / pathology. Hematologic Neoplasms / diagnosis. Hematologic Neoplasms / pathology. Humans. Neoplasm Metastasis. Pericardium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14728061.001).
  • [ISSN] 1175-3277
  • [Journal-full-title] American journal of cardiovascular drugs : drugs, devices, and other interventions
  • [ISO-abbreviation] Am J Cardiovasc Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 62
  •  go-up   go-down


21. Kisselbach C, Ristic AD, Pankuweit S, Karatolius K, Maisch B: [Women and pericardial neoplastic manifestations of the heart and pericardium]. Herz; 2005 Aug;30(5):409-15; quiz 429-30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Women and pericardial neoplastic manifestations of the heart and pericardium].
  • Despite the proportions, most women believe that heart disease is a man's disease and that they will die of breast cancer.
  • Data on epidemiology and incidence are rare: there is only an estimated incidence of cardiac neoplasm at necropsy ranging from 0,001% to 0,3%.
  • The majority of the primary tumors are benign.
  • The most common tumor entity is benign cardiac myxoma.
  • Malignant heart tumors are less common.
  • Most often they are different types of sarcomas, which have a poor outcome and affect more males than females.
  • Metastatic tumors of the heart are 100 times more common than the primary ones.
  • They originate mainly from melanomas, leukemias, lymphomas, and cancer, especially of the lung or breast.
  • Indeed in women breast cancer is the most common metastatic tumor associated with pericardial effusion.
  • To prevent death from tamponade, pericardiocentesis, in addition to the systemic chemotherapy, is mandatory, best when instillation of chemotherapeutics (cisplatin or thiotepa) or radioisotopes is given into the pericardial sac to prevent recurrence of the effusion.
  • However, more of the malignant tumors may be curable if exactly diagnosed at an earlier stage.
  • METHODS: A retrospective study was conducted of all patients with cardiac and pericardial neoplasm exactly diagnosed by endomyocardial or epicardial biopsy and pericardiocentesis, using hospital medical records and a biopsy and pericardiocentesis registry from 2000-2005 with 297 patients.
  • Pericardial effusion and biopsy analyses included biochemistry, cytology, serology, microbiology, histology, immunohistology, and polymerase chain reaction (PCR).
  • RESULTS: In 76 cases (25.6%) a neoplasm was the reason for a pericardial effusion.
  • 36 women suffered from the breast carcinoma (47%) and 40 males lung cancer (42%) as the firstly metastatic tumor.
  • There was no recurrence of a relevant pericardial effusion in patients who were treated by intrapericardial instillation of cisplatin (30 mg/m2 body surface in 100 ml 0.9% NaCl).
  • CONCLUSION: Females are more often affected by primary cardiac tumors than males with an excellent outcome.
  • By contrast, the preventive checkup and aftercare will gain more prognostic importance, especially in case of breast cancer, to earlier recognize a secondary cardiac neoplasm by biopsy and pericardiocentesis with intrapericardial treatment of neoplastic pericarditis.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132244.001).
  • [ISSN] 0340-9937
  • [Journal-full-title] Herz
  • [ISO-abbreviation] Herz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


22. Inoue Y, Tsukasaki K, Nagai K, Soda H, Tomonaga M: Durable remission by sobuzoxane in an HIV-seronegative patient with human herpesvirus 8-negative primary effusion lymphoma. Int J Hematol; 2004 Apr;79(3):271-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remission by sobuzoxane in an HIV-seronegative patient with human herpesvirus 8-negative primary effusion lymphoma.
  • Primary effusion lymphoma (PEL) is recognized as a unique clinicopathological entity associated with human herpesvirus 8 (HHV-8), and it occurs almost exclusively in human immunodeficiency virus (HIV)-infected individuals.
  • In the majority of PEL cases, Epstein-Barr virus (EBV) has been found in the tumor cells as well.
  • We describe here an elderly HIV seronegative female patient with PEL in the pleura and pericardium not associated with HHV-8 or EBV.
  • Recurrence of PEL in the pericardium as effusion lymphoma was found 3 months after the discontinuation of CHOP.
  • After approximately 1 year of intermittent multiagent salvage therapy for pericardial recurrences, a treatment that resulted in a partial response, 3 cycles of monotherapy with sobuzoxane were administered.
  • At the time of this report the patient had been free from PEL for more than 18 months without chemotherapy.
  • [MeSH-major] Piperazines / administration & dosage. Pleural Effusion, Malignant / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA, Viral / analysis. Disease-Free Survival. Female. HIV Seronegativity. Herpesvirus 8, Human / genetics. Humans. Remission Induction / methods

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15168597.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Piperazines; R1308VH37P / sobuzoxane
  • [Number-of-references] 24
  •  go-up   go-down


23. Chrissos DN, Stougiannos PN, Mytas DZ, Katsaros AA, Andrikopoulos GK, Kallikazaros IE: Multiple cardiac metastases from a malignant melanoma. Eur J Echocardiogr; 2008 May;9(3):391-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cardiac metastases from a malignant melanoma.
  • Metastatic tumors in the pericardium or the heart are more common than primary tumors and their incidence has increased during the last decades due to the prolonged survival of patients with cancer and the increased prevalence of the disease in the general population.
  • He had a history of a malignant skin melanoma surgically removed 4 years ago.
  • The echo study identified multiple metastases in the heart involving the pericardium, the myocardium and the right atrium, where the tumor was mobile creating mechanical tricuspid valve stenosis.
  • Malignant metastasis was confirmed by pericardiocentesis and, although treatment with chemotherapy was promptly initiated, the patient died 4 months later.
  • Despite the difficulty in clinical diagnosis of cardiac melanoma, early detection has important therapeutic and prognostic implications.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347051.001).
  • [ISSN] 1532-2114
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Zigrossi P, Brustia M, Bobbio F, Campanini M: Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report. Ann Ital Med Int; 2001 Apr-Jun;16(2):112-7
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report.
  • Tumor lysis syndrome, which develops after effective therapy of malignant conditions and leads to hyperuricemia, hyperkaliemia, hyperphosphatemia, hypocalcemia and elevated lactate dehydrogenase, is uncommon in solid tumors.
  • In breast carcinoma it can be associated with tamoxifen flare, i.e. a transient increase in symptoms, mainly bone pain, observed shortly after the start of tamoxifen therapy.
  • We report the case of a patient with advanced breast carcinoma involving the pleural space, unresponsive to combined chemotherapy, who experienced rapid worsening after the initiation of letrozole.
  • Her symptoms included shock, bilateral pleural effusion, cardiac tamponade and oliguria.
  • This clinical picture suggests increased damage to the pleura (and probably the pericardium) and rapid leakage of tumor products, following the start of endocrine therapy.
  • Letrozole is a non-steroidal aromatase inhibitor which is used in advanced breast cancer, resistant to first-line endocrine/chemotherapeutic treatment.
  • Our review of the literature did not disclose any other descriptions of flare and tumor lysis syndrome after aromatase inhibitor therapy.
  • The aim of this presentation is to point out the practical significance, in neoplastic patients, of the differential diagnosis between symptoms due to tumor progression and those associated with anomalous reactions to therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Breast Neoplasms / drug therapy. Nitriles / adverse effects. Triazoles / adverse effects. Tumor Lysis Syndrome / etiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11688358.001).
  • [ISSN] 0393-9340
  • [Journal-full-title] Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna
  • [ISO-abbreviation] Ann. Ital. Med. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  • [Number-of-references] 31
  •  go-up   go-down


25. Vigneswaran WT, Stefanacci PR: Pericardial mesothelioma. Curr Treat Options Oncol; 2000 Oct;1(4):299-302
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial mesothelioma.
  • Primary pericardial mesothelioma is a rare but lethal disease.
  • In most cases the diagnosis is made at autopsy or postoperatively.
  • Clinical signs and symptoms are typically nonspecific and are similar to compromised cardiac function.
  • Surgical resection remains the main treatment modality.
  • Most often the tumor invades the myocardium or the great vessels and therefore is at best palliative in relieving pericardial tamponade or constriction.
  • Addition of chemotherapy or radiation has been disappointing.
  • Newer therapeutic approaches for malignant pleural mesothelioma are likely to influence the treatment of pericardial mesothelioma in the future.
  • [MeSH-major] Heart Neoplasms / therapy. Mesothelioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Pericardium / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1995 Jul;222(1):78-86 [7618973.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1559-65 [8336195.001]
  • [Cites] J Nucl Med. 1987 Jul;28(7):1210-2 [3474368.001]
  • [Cites] Am Heart J. 1988 Jun;115(6):1321-2 [3376853.001]
  • [Cites] Am Heart J. 1992 Sep;124(3):802-3 [1514518.001]
  • [Cites] Ann Surg Oncol. 1995 May;2(3):214-20 [7641017.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Am Rev Respir Dis. 1978 Aug;118(2):419-24 [697191.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):660-1 [7993848.001]
  • [Cites] J Cardiovasc Surg (Torino). 1994 Jun;35(3):261-7 [8040178.001]
  • [Cites] Cardiovasc Clin. 1976;7(3):257-69 [1000541.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2577-82 [10375105.001]
  • [Cites] Environ Res. 1980 Dec;23(2):270-81 [7472312.001]
  • [Cites] Tex Heart Inst J. 1994;21(2):170-4 [8061543.001]
  • [Cites] Chest. 1982 Apr;81(4):520-3 [7067523.001]
  • [Cites] Postgrad Med J. 1992 Feb;68(796):137-9 [1570257.001]
  • [Cites] Am Heart J. 1986 May;111(5):986-8 [3706117.001]
  • [Cites] Cancer. 1970 Oct;26(4):914-9 [5506612.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1987;21(3):273-5 [3438724.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(6):420-6 [1934246.001]
  • (PMID = 12057155.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


26. Tomkowski WZ, Wiśniewska J, Szturmowicz M, Kuca P, Burakowski J, Kober J, Fijałkowska A: Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer; 2004 Jan;12(1):53-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade.
  • GOALS: To evaluate the effectiveness and side effects of intrapericardial administration of cisplatin in prevention of recurrent malignant pericardial effusion.
  • The diagnosis of malignancy was based upon histological examination of samples from primary tumor.
  • The majority of patients suffered from a neoplasm localized in the thorax (41 out of 46 patients; 89%).
  • In 35 cases, pericardiocentesis, and in 11 cases, video-assisted thoracoscopic surgery (VATS) of pericardium was performed.
  • Malignant etiology of pericardial fluid was confirmed by cytological examination, histology being obtained by VATS pericardial biopsy or by echocardiography (ECG).
  • If daily drainage of pericardial fluid observed during 5-7 days exceeded 50 ml, cisplatin was instilled according to one of three regimens:.
  • (1) 10 mg of cisplatin dissolved in 20 ml of normal saline administered over 5 min during 5 consecutive days directly into the pericardial space (39 patients);.
  • Treatment was considered as successful when recurrence of symptoms of large pericardial effusion was not observed in ECG and other interventions directed to the pericardium were not required.
  • Efficacy of investigated treatment was assessed also in the group of patients with survival longer than 30 days.
  • Safety of treatment was assessed in the whole group of patients.
  • Positive effect of intrapericardial treatment with cisplatin was achieved in 43 out of 46 patients (93.5%) in the entire investigated group and in 35 out of 38 patients (92%) who survived more than 30 days.
  • In the subgroup of patients with non-small cell lung cancer (NSCLC) and survival longer than 30 days, high efficacy was documented (29 out of 31 cases; 93.5%).
  • Median survival time in the group of 38 patients who survived more than 30 days was 102.5 days.
  • Sclerosis of the pericardial space without symptoms of constriction occurred in five out of 46 cases (10.9%).
  • CONCLUSIONS: Cisplatin administered directly into the pericardial space is a very effective and relatively safe method of treatment of recurrent malignant pericardial effusion, especially in the course of NSCLC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cardiac Tamponade / etiology. Cisplatin / administration & dosage. Lung Neoplasms / surgery. Pericardial Effusion / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Small Cell / surgery. Drainage. Female. Humans. Injections, Intralesional. Male. Middle Aged. Pericardiocentesis / adverse effects. Pericardium. Recurrence. Survival Analysis. Thoracic Surgery, Video-Assisted / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 1997 Mar;16(2-3):215-22 [9152952.001]
  • [Cites] JAMA. 1994 Jul 6;272(1):59-64 [8007081.001]
  • [Cites] Chest. 1999 Aug;116(2):275-6 [10453849.001]
  • [Cites] Monaldi Arch Chest Dis. 1995 Apr;50(2):86-8 [7613552.001]
  • [Cites] Oncology. 1994 Nov-Dec;51(6):507-9 [7526307.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3141-7 [8955660.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):437-42 [1617593.001]
  • [Cites] Am J Med. 1998 Aug;105(2):106-9 [9727816.001]
  • [Cites] Mayo Clin Proc. 1998 Jul;73(7):647-52 [9663193.001]
  • [Cites] Cancer. 1990 Mar 15;65(6):1456-9 [2306690.001]
  • [Cites] Chest. 1996 Jun;109(6):1452-4 [8769492.001]
  • [Cites] Herz. 2000 Dec;25(8):787-93 [11200128.001]
  • [Cites] Support Care Cancer. 1997 Jan;5(1):64-6 [9010992.001]
  • [Cites] Ann Thorac Surg. 1997 Nov;64(5):1422-7; discussion 1427-8 [9386714.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2371-6 [9667253.001]
  • [Cites] Chest. 1998 Apr;113(4):861-6 [9554616.001]
  • [Cites] Mayo Clin Proc. 2000 Mar;75(3):248-53 [10725950.001]
  • [Cites] Monaldi Arch Chest Dis. 1997 Jun;52(3):221-4 [9270245.001]
  • [Cites] Am J Cardiol. 1987 Nov 15;60(14):1161-6 [2446487.001]
  • [Cites] Circulation. 1962 Aug;26:228-41 [14037856.001]
  • [Cites] J Cardiothorac Vasc Anesth. 1993 Apr;7(2):178-83 [8477023.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Sep;112(3):637-43 [8800150.001]
  • [Cites] JAMA. 1987 Feb 27;257(8):1088-92 [3806903.001]
  • [Cites] Chest. 1997 Oct;112(4 Suppl):291S-295S [9337306.001]
  • [Cites] Eur Heart J. 2002 Oct;23(20):1625-31 [12323163.001]
  • (PMID = 14505155.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Ishibashi H, Shimoyama T, Akamatsu H, Sunamori M, Ohtani T, Imai K: [A successfully resected case of giant malignant mediastinal germ cell tumor]. Kyobu Geka; 2002 Aug;55(9):815-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A successfully resected case of giant malignant mediastinal germ cell tumor].
  • After 2 courses of chemotherapy [cisplatin (CDDP) and etoposide (VP-16)], serum AFP level decreased to 25 ng/ml, and the tumor was resected with pericardium (the tumor size was 14 x 10 x 20 cm).
  • Two courses of chemotherapy were administered again postoperatively with normalization of serum AFP level.
  • The patient has no sign of recurrence of the tumor.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Male. Treatment Outcome. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174631.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Hasegawa S, Tanaka F: Malignant mesothelioma: current status and perspective in Japan and the world. Gen Thorac Cardiovasc Surg; 2008 Jul;56(7):317-23
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma: current status and perspective in Japan and the world.
  • Malignant pleural mesothelioma (MPM) is associated with a poor prognosis; and to make things worse, its incidence is increasing throughout the world.
  • Surgical management of MPM is comprised of two aspects: diagnosis and resection.
  • Surgical biopsy with thoracoscopy provides a higher yield but a higher rate of tumor cell seeding than blind biopsy.
  • There are two types of surgical resection for MPM.
  • Pleurectomy/decortication (P/D) involves removal of as much of the visceral, parietal, and pericardial pleura and the tumor as possible without removing the underlying lung.
  • EPP comprises en bloc resection of visceral, parietal, and pericardial pleura and adjacent components such as ipsilateral lung, pericardium, and diaphragm, without opening the pleural cavity.
  • EPP was considered a highly dangerous procedure with a surgical mortality of more than 30% decades ago, but its current operative mortality/morbidity rates are 4%-9% and 60%, respectively.
  • As macroscopic complete resection is the primary goal of surgery for MPM because of its diffuse intrapleural growth, surgical resection alone is associated with poor survival.
  • In this context, combination therapy with surgery plus chemotherapy and/or radiotherapy is currently considered the standard treatment for patients with respectable MPM.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy. Thoracic Surgical Procedures
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Humans. Japan. Laparoscopy. Mediastinoscopy. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant. Thoracoscopy. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 1999 Dec;16(6):619-23 [10647830.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2629-30 [12860935.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1039-47 [10587144.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Oncologist. 2007 Jul;12(7):850-63 [17673616.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 May;131(5):981-7 [16678579.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 May;31(5):765-70; discussion 770-1 [17337201.001]
  • [Cites] Ann Thorac Surg. 2005 Dec;80(6):1988-92; discussion 1992-3 [16305830.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Radiology. 2006 Nov;241(2):589-94 [17005770.001]
  • [Cites] Eur J Radiol. 2007 Dec;64(3):356-66 [17954021.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):389-93 [8319170.001]
  • [Cites] Interact Cardiovasc Thorac Surg. 2008 Feb;7(1):102-6 [18048410.001]
  • [Cites] Chest. 2003 Feb;123(2):551-61 [12576380.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1183-5 [15451229.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):175-6 [17409850.001]
  • [Cites] Br J Cancer. 1998 Mar;77(6):907-12 [9528833.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1172-8 [8501504.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S27-32 [15950796.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):489-94 [8876892.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S25-6 [15950795.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):25-30 [10458214.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Sep;130(3):905-6 [16153957.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S71-4 [15950805.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):342-5 [11875695.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Apr;29(4):579-84 [16495068.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1774-6 [15511473.001]
  • [Cites] J Thorac Imaging. 2006 May;21(2):146-53 [16770231.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1224-30 [11571736.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Am J Ind Med. 2006 Jan;49(1):1-7 [16362942.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1249-53 [17066226.001]
  • [Cites] Ann Thorac Surg. 2006 Dec;82(6):2337; author reply 2337-8 [17126172.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):57-65 [11162867.001]
  • [Cites] Kyobu Geka. 2007 Jan;60(1):19-24 [17249533.001]
  • [Cites] Ann Thorac Surg. 2007 Nov;84(5):1685-92; discussion 1692-3 [17954086.001]
  • [Cites] J Nucl Med. 2007 Sep;48(9):1449-58 [17704250.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3451-7 [15337794.001]
  • [Cites] J Thorac Oncol. 2007 Oct;2(10):957-65 [17909360.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):279-87 [11679187.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):487-92 [2106209.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jan;29(1):14-9 [16343925.001]
  • [Cites] Thorax. 2007 Nov;62 Suppl 2:ii1-ii19 [17965072.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Jun;133(6):1414-8 [17532931.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):367-72 [9352954.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Feb;11(2):210-3 [9080144.001]
  • [Cites] Lung Cancer. 2007 Aug;57 Suppl 2:S24-9 [17686442.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5 [16751058.001]
  • (PMID = 18607677.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 60
  •  go-up   go-down


29. Rafajlovski S, Tatić V, Ilić S, Kanjuh V: [Frequency of metastatic tumors in the heart]. Vojnosanit Pregl; 2005 Dec;62(12):915-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Secondary or metastatic tumors in the heart occur more frequently than primary ones, and, according to the published series, their frequency found in autopsic material ranges from 1.6% to 20.6%.
  • The aim of this study was to analyze the frequency of metastatic tumors of the heart, their primary localization, as well as the localization of the metastases found in the autopsic material within the period 1972-2004.
  • METHODS: During the autopsy of the patients died of metastatic tumors, we microscopically and macroscopically analyzed all the organs and tissues to determine the metastases of primary tumors in other organs, especially in the heart and pericardium.
  • In 2 928 (25.6%) out of 11 403 autopsies, the presence of malignant tumor was diagnosed, and in 79 (2.7%) of these cases, metastasis of the heart was found out.
  • The most frequent metastases in the heart were caused by pulmonary carcinoma (18 cases), leukemia and malignant lymphoma (8 cases, each), then pancreatic and breast carcinoma, while the metastases of other carcinomas were rather rare.
  • In 40 (60.76%) cases, the metastasis was localized in the myocardium, but more often in the left ventricle, in 24 (30.38%) cases in the pericardium, in 4 cases in the epicardium and in the 3 of them in the mitral and tricuspid valve.
  • The methods of choice for the diagnosis of the metastasis in the heart are echocardiography, computerized tomography, magnetic resonance imaging, cytological analysis of the pericardial effusion and biopsy.
  • The treatment includes surgery, chemotherapy and radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16375220.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


30. Sugimoto T, Kobayashi M, Okabayashi T, Hokimoto N, Nishimori H, Yamasaki F, Moriki T, Takahashi T, Sasaguri S, Araki K: [A case of recurrent breast cancer causing malignant pericardial effusion successfully managed with instillations of cisplatin]. Gan To Kagaku Ryoho; 2005 Sep;32(9):1311-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent breast cancer causing malignant pericardial effusion successfully managed with instillations of cisplatin].
  • A 44-year-old female patient was admitted to our hospital because of dyspnea caused by malignant cardiac tamponade 2 years and 8 months after standard radical mastectomy for a stage III breast cancer.
  • Malignant pericardial effusion was diagnosed by echocardiography and differentiated by cytology.
  • Pericardiocentesis improved her hemodynamics and 9 consecutive pericardial instillations of cisplatin (10 mg) prevented reaccumulation of pericardial effusion, which had never reoccurred until she died of breast cancer one year and 6 months later.
  • Therefore, it is suggested that instillation of cisplatin is one of the beneficial alternatives to surgical treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Cisplatin / administration & dosage. Pericardial Effusion / drug therapy
  • [MeSH-minor] Adult. Female. Heart Neoplasms / secondary. Humans. Lymphatic Metastasis. Mastectomy, Radical. Pericardiocentesis. Pericardium. Quality of Life. Secondary Prevention

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184930.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Jung JI, Kim HH, Park SH, Song SW, Chung MH, Kim HS, Kim KJ, Ahn MI, Seo SB, Hahn ST: Thoracic manifestations of breast cancer and its therapy. Radiographics; 2004 Sep-Oct;24(5):1269-85
MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic manifestations of breast cancer and its therapy.
  • Breast cancer is the second most common cause of cancer-related death in women.
  • In most patients, imaging demonstrates thoracic changes resulting from either treatment, complications of treatment, or tumor recurrence or metastasis.
  • Radiation therapy frequently causes radiation pneumonitis, which occurs approximately 4-12 weeks after the completion of therapy and is characteristically limited to the field of irradiation.
  • Chemotherapy-related complications include cardiotoxicity, pneumonitis, and infection.
  • Ultrasonography and computed tomography are more sensitive than physical examination for detecting local and regional recurrence.
  • The thorax is a common site of metastasis, which may affect the lymph nodes, bone, lung, pleura, or heart and pericardium.
  • Bone metastasis is usually evaluated with bone scintigraphy and may cause spinal cord compression, a serious complication that requires early diagnosis.
  • Familiarity with the spectrum of radiologic findings in breast cancer patients allows accurate image interpretation and correct diagnosis.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Artifacts. Female. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lymphatic Metastasis / radiography. Mammaplasty. Mastectomy / adverse effects. Mastectomy / methods. Middle Aged. Neoplasm Recurrence, Local / radiography. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / radiography. Pneumonia / chemically induced. Pneumonia / radiography. Postoperative Complications / etiology. Postoperative Complications / radiography. Radiation Injuries / radiography. Radiotherapy / adverse effects. Seroma / radiography. Spinal Cord Compression / etiology. Spinal Cord Compression / radiography. Spinal Neoplasms / radiography. Spinal Neoplasms / secondary. Thoracic Neoplasms / radiography. Thoracic Neoplasms / secondary. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2004
  • [ErratumIn] Radiographics. 2004 Nov-Dec;24(6):1610
  • (PMID = 15371608.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


32. Scripcariu V, Dajbog E, Lefter L, Ferariu D, Pricop A, Grigoraş M, Dragomir C: [Malignant peritoneal mesothelioma]. Chirurgia (Bucur); 2006 Nov-Dec;101(6):641-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma].
  • [Transliterated title] Mezoteliomul malign peritoneal.
  • Mesothelioma is a neoplasm originating from the mesothelial surface lining cells of the serous human cavities.
  • It may involve the pleura, less frequently the peritoneum rarely, the pericardium, the tunica vaginalis testis and ovarian epithelium.
  • A causal relationship between asbestos exposure and pleural, peritoneal and pericardial malign mesothelioma was suggested, the risk of cancer being correlated to cumulate exposure.
  • Studies from National Cancer Institute, USA, show that the malignant mesothelioma is a rare and aggressive asbestos related malignancy.
  • The symptomatology is insidious and poses difficult problems in diagnosis and treatment.
  • This paper presents the case of a 59 year old patient with malignant peritoneal mesothelioma who worked almost 40 years as an electrician, exposed to asbestos fibers.
  • He was hospitalized for important weight loss, abdominal pain and tiredness being diagnosed after imaging tests with a giant tumor, localized at the abdominal upper level, which seems to originate from the spleen's superior pole.
  • During surgery we discovered a tumor with cystic parts, intense vascularized, which turn to be adherent in the upper side to the lower face of the left midriff cupola, to the spleen superior pole and 1/3 middle level of the great gastric curve.
  • It was performed surgical ablation of the tumor, splenectomy with favorable postoperative evolution, the patient being now under chemotherapy treatment.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Middle Aged. Splenectomy. Tomography, X-Ray Computed. Treatment Outcome


33. Pavón Jiménez R, García Rubira JC, García Martínez JT, Sánchez Escribano R, Calvo Jambrina R, Cruz Fernández JM: [Intrapericardial cisplatin for malignant tamponade]. Rev Esp Cardiol; 2000 Apr;53(4):587-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intrapericardial cisplatin for malignant tamponade].
  • The choice therapy of malignant pericardial effusion is controversial.
  • Several different approaches have been advocated in order to prevent reaccumulation of the pericardial fluid, most of them quite cumbersome.
  • There were 6 patients, and the primary tumor was breast carcinoma in 2, lung in 1, ovary in 1, mediastinal fibrosarcoma in 1, and unknown in 1.
  • Administration of cisplatin was virtually uneventful and painless, and there were no recurrences, with a survival of 2 to 18 months (mean 5.6).We conclude that intrapericardial cisplatin is safe and effective in treating malignant pericardial tamponade and preventing recurrence.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cardiac Tamponade / drug therapy. Cardiac Tamponade / etiology. Cisplatin / therapeutic use. Heart Neoplasms / complications. Heart Neoplasms / drug therapy. Pericardial Effusion / drug therapy. Pericardial Effusion / etiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Pericardium

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10758038.001).
  • [ISSN] 0300-8932
  • [Journal-full-title] Revista española de cardiología
  • [ISO-abbreviation] Rev Esp Cardiol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] SPAIN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Hassan R, Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer; 2008 Jan;44(1):46-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelin targeted cancer immunotherapy.
  • Mesothelin is a tumour differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium.
  • It is, however, highly expressed in several human cancers including malignant mesothelioma, pancreatic, ovarian and lung adenocarcinoma.
  • The normal biologic function of mesothelin is unknown but recent studies have shown that it binds to CA-125 and may play a role in the peritoneal spread of ovarian cancer.
  • The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy.
  • These ongoing clinical trials will help define the utility of mesothelin as a target for cancer therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cancer Vaccines. Immunotherapy / methods. Membrane Glycoproteins / drug effects. Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. GPI-Linked Proteins. Genetic Vectors / therapeutic use. Humans. Listeria monocytogenes

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):559-65 [16794638.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):563-70 [17400285.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4547-51 [12907630.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] BMC Dev Biol. 2003 Apr 7;3:2 [12697065.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9190-8 [14676194.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):357-66 [15017593.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1327-35 [15274292.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):297-306 [15289501.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7 [15365184.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):373-81 [1735605.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):259-68 [1599018.001]
  • [Cites] Int J Cancer. 1992 Jun 19;51(4):548-54 [1351045.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):805-8 [8288629.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):669-74 [9435250.001]
  • [Cites] Nat Biotechnol. 1999 Jun;17(6):568-72 [10385321.001]
  • [Cites] Gene Ther. 2005 Jan;12(2):187-93 [15526007.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3814-20 [15897581.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1201-9 [16000290.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7 [16082249.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6342-51 [16144939.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124(6):838-45 [16416732.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31 [16467095.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4695-701 [16899620.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4983-8 [16914588.001]
  • [Cites] Mol Cancer. 2006;5(1):50 [17067392.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):1-16 [17056092.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1571-5 [17332303.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7860-72 [10630639.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2902-6 [10733593.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):145-56 [11134207.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3520-6 [12429643.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):150-8 [12548160.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5144-9 [17785569.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • (PMID = 17945478.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010510-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / GPI-Linked Proteins; 0 / MORAb-009 monoclonal antibody; 0 / Membrane Glycoproteins; 0 / SS1(dsFv)PE38; 0 / mesothelin
  • [Number-of-references] 46
  • [Other-IDs] NLM/ NIHMS38546; NLM/ PMC2265108
  •  go-up   go-down


35. Kiraç FS: [Radiation and the heart]. Anadolu Kardiyol Derg; 2001 Dec;1(4):276-82, AXVI

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of radiotherapy in the management of malignant tumors causes low or high radiation exposure doses to normal tissues and undesired side effects may occur in early and late period following irradiation.
  • All mediastinal structures, lungs and heart can exposure to total therapeutic dose during radiation therapy for thoracal or mediastinal malignancies such as Hodgkin disease and breast cancer.
  • While early deaths following irradiation are caused by primary malignancies among these patients, long-term mortalities are resulted from radiation-induced morphological and functional organ abnormalities.
  • Cardiac changes are the most frequently seen.
  • Significant cardiac anatomical changes occur particularly in pericardium, myocardium, valves and result in severe cardiac dysfunctions after 10 to 20 years following administration of radiation into mediastinal or thoracal areas.
  • The precision of the development of radiation-induced cardiovascular complications has increased due to achieving the complete cure of primary tumor and to the extended survival time of irradiated cases by using advanced radiotherapy and adjuvant chemotherapy modalities.
  • Early detection of radiation-induced morphological changes leading to cardiac dysfunction offers the possibility for early intervention such as administration of cardiovascular drugs and/or cardiac surgery in order to reduce or delay severe irreversible late complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12101838.001).
  • [ISSN] 1302-8723
  • [Journal-full-title] Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
  • [ISO-abbreviation] Anadolu Kardiyol Derg
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 39
  •  go-up   go-down


36. Reardon KA, Reardon MA, Moskaluk CA, Grosh WW, Read PW: Primary pericardial malignant mesothelioma and response to radiation therapy. Rare Tumors; 2010;2(3):e51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pericardial malignant mesothelioma and response to radiation therapy.
  • We report a case of a primary pericardial malignant mesothelioma.
  • Cardiac magnetic resonance imaging revealed a large mass in the pericardium attached to the right ventricle.
  • Partial resection of the mass was undertaken revealing malignant mesothelioma, byphasic type.
  • The patient was treated with chemotherapy intermittently over a period of 3 years, but his disease continued to progress.
  • The patient was then treated with definitive radiation therapy to 64 Gy to the primary tumor using a six field 3D conformal technique.
  • The patient remains free of progressive disease 86 months from the time of diagnosis and 50 months from the completion of his radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139966.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994533
  • [Keywords] NOTNLM ; pericardial mesothelioma / radiation
  •  go-up   go-down


37. Matsakas EP, Lazaros GA, Panou FK, Karavidas AI, Papalimberi EP, Scotis ID, Zacharoulis AA: Primary pericardial fibrosarcoma presenting as "near" cardiac tamponade. Clin Cardiol; 2002 Feb;25(2):83-5
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pericardial fibrosarcoma presenting as "near" cardiac tamponade.
  • Diagnostic investigations, such as echocardiography and magnetic resonance imaging, provided evidence of a large mass within the pericardial sac, attached by a broad base to the parietal pericardium and lying along the right ventricular free wall.
  • A partial pericardiectomy was performed to relieve the patient's symptoms, and histologic examination of a biopsy specimen showed features of a malignant, spindle cell, mesenchymal neoplasm.
  • The patient underwent surgical treatment during which the tumor was found to infiltrate the anterior surface of the right ventricle.
  • Histologically, the tumor was identified as a high-grade fibrosarcoma, and additional chemotherapy was given.
  • [MeSH-major] Cardiac Tamponade / etiology. Fibrosarcoma / diagnosis. Heart Neoplasms / diagnosis. Pericardium
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11841156.001).
  • [ISSN] 0160-9289
  • [Journal-full-title] Clinical cardiology
  • [ISO-abbreviation] Clin Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Nascimento AF, Winters GL, Pinkus GS: Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder. Am J Surg Pathol; 2007 Sep;31(9):1344-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder.
  • Primary lymphomas of the heart are rare and frequently are diagnosed at autopsy.
  • Modern imaging technology now permits early diagnosis and treatment.
  • This report describes the clinical, histologic, immunophenotypic, and molecular genetic findings for 5 patients with malignant lymphoma restricted to the cardiac muscle, with or without pericardial involvement.
  • The right atrium was involved in all cases with the left atrium, right ventricle, and pericardium affected in 1 case each.
  • Clinical presentation included pericardial effusions associated with precordial pain, dyspnea, and bradycardia.
  • In all cases, biopsy or resection of the lesion or cytologic examination of the pericardial fluid established a diagnosis.
  • One patient died shortly after diagnosis due to cerebral infarction.
  • Two patients are alive without disease after chemotherapy with CHOP after 120 and 192 months.
  • One patient underwent chemotherapy with CHOP and rituximab, and shows persistent cardiac involvement by lymphoma but with a decrease in tumor burden at 7 months of follow-up.
  • Clinical outcome is variable; however, early diagnosis in conjunction with effective treatment (surgery and/or chemotherapy) may result in an excellent prognosis.
  • Primary cardiac lymphoma should be included in the differential diagnosis of a right atrial mass.
  • [MeSH-major] Antigens, CD / analysis. Gene Expression Regulation, Neoplastic. Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Gene Rearrangement. Genotype. Heart Atria / pathology. Heart Ventricles / pathology. Humans. Immunophenotyping. Karyotyping. Middle Aged. Pericardium / pathology. Prednisone / administration & dosage. Prednisone / therapeutic use. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721189.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down






Advertisement